RxDoctor Payments Data

Deborah Forst, MD

Neurology · Boston, MANPI 1770800146

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $525 of the $525 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Merck. That places this record below the midpoint for neurology clinicians in MA, where the typical reported total is $350.

$525in general payments, 2019–2025

Across 1 payment — averaging $525.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$525
$69,175in research payments, 2019–2025

Across 23 payments — averaging $3007.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$37K
  • Daiichi Sankyo Inc.$30K
  • Bristol Myers Squibb$2K
  • Taiho Oncology, Inc.$500

What the payments were for

  • Consulting fees$525100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$525

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$525 in reported general payments places this provider in the 50th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$60,369
Medicare patients
156
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Duloxetine Hcl16$426
Gabapentin15$237
Levetiracetam11$156

Paid to pharmacies, not to this prescriber.

Other neurology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →